SCHEMBL9664951

SCHEMBL9664951

CC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)c1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 19/20 0.72
▸ ABCG2 Q9UNQ0 4/20 0.72
▸ ABCB11 O95342 3/20 0.72
▸ CYP8B1 Q9UNU6 3/20 0.72
▸ LMNA P02545 3/20 0.72
▸ CYP51A1 Q16850 3/20 0.72
▸ FYN P06241 2/20 0.72
▸ MEN1 O00255 2/20 0.72
▸ ABCB1 P08183 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ HIF1A Q16665 2/20 0.72
▸ CXCR1 P25024 1/20 0.72
▸ TACR1 P25103 1/20 0.72
▸ AVPR2 P30518 1/20 0.72
▸ CCR4 P51679 1/20 0.72
▸ PDE4D Q08499 1/20 0.72
▸ CYP17A1 P05093 5/20 0.64
▸ CYP19A1 P11511 4/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17739438 1.00 CYP3A4 (0.72) CYP3A4ABCG2ABCB11CYP8B1LMNA
SCHEMBL4152523 0.95 ABCG2 (0.71) CYP3A4ABCG2ABCB11CYP8B1LMNA
SCHEMBL4152531 0.95 ABCG2 (0.71) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL1650334 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL17739437 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL65702 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL2615053 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL4149722 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Saperconazole SCHEMBL65701 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA
Itraconzole SCHEMBL12887924 0.94 CYP3A4 (0.79) CYP3A4ABCG2ABCB11CYP8B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2017-08-03 — — US disclosed
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2017-08-03 — — US disclosed
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2016-05-12 — — US disclosed
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS THE SCRIPPS RESEARCH INSTITUTE 2016-05-12 — — US disclosed
EP-0283992-B1 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones JANSSEN PHARMACEUTICA N.V. (BE) 1992-09-16 — — EP disclosed
EP-0283992-A2 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones JANSSEN PHARMACEUTICA N.V. (BE) 1988-09-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130258-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS MMP1, COL2A1, MMP8 CYP3A4 4660/4885ABCG2 3265/4885ABCB11 2310/4885
US-20170217943-A1 SMALL MOLECULE INHIBITORS OF FIBROSIS MMP1, COL2A1, MMP8 CYP3A4 4660/4885ABCG2 3265/4885ABCB11 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback